You are here

  • Home
  • Archive
  • Volume 9, Issue 3
  • Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells

Article metrics

Article menu
Basic tumor immunology
Original research
Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells

 

Online download statistics by month:

Online download statistics by month: March 2021 to March 2024

AbstractFullPdf
Mar 2021972972311
Apr 2021557557144
May 202126226288
Jun 2021171171108
Jul 202117217279
Aug 2021169169105
Sep 202111411485
Oct 2021878763
Nov 202110310160
Dec 202111611747
Jan 202219820342
Feb 2022727660
Mar 2022718039
Apr 20229910349
May 2022666661
Jun 2022697355
Jul 2022606248
Aug 2022737536
Sep 2022777957
Oct 2022555542
Nov 2022575953
Dec 2022545416
Jan 2023959527
Feb 2023868738
Mar 2023585835
Apr 2023444523
May 2023383917
Jun 2023434317
Jul 2023575735
Aug 2023696941
Sep 2023444414
Oct 2023414118
Nov 2023505014
Dec 2023434313
Jan 2024424315
Feb 2024434316
Mar 2024424344
Total446945072015